DALLAS — Neurolens, a company commercializing solutions to optimize vision, has completed a $67 million financing.
Neurolenses “are the first and only prescription lenses that go beyond visual acuity to provide comfort for the majority of adults who complain of headaches, neck/shoulder pain and eyestrain when using digital devices, reading or doing detail work,” according to the company.
The Neurolens Contoured Prism design “helps the eyes work together comfortably, bringing the eyes into alignment to relieve painful symptoms.”
The financing was led by MVM Partners, with additional participation from Falcon Vision/KKR, Marshall Wace, and existing investors including Bluestem Capital.
The investment “will fuel continued product innovation and growth initiatives, further accelerating the adoption of Neurolens,” according to a press release.
“While we have grown tenfold in the past three years, the unmet patient need remains massive,” said Pierre Bertrand, Neurolens CEO. “Nearly 6 out of 10 Americans are reporting daily symptoms of Digital Vision Syndrome, and we are excited to continue bringing solutions to independent optometry to meet their needs. We are grateful to see both current and new investors embrace our mission to transform eyecare beyond visual acuity.”
Dr. Eric Bednarski, partner at MVM, said, “Neurolens offers a remarkable solution to address the widespread problems that patients experience due to DVS. We are pleased to partner with Neurolens to support its continued growth.”
Dr. Akhilesh Pathipati, partner at MVM, said, “The team at Neurolens has shown tremendous leadership and dedication while innovating in a market poised for growth. We are thrilled to work with them to continue changing the lives of patients.”
Bednarski and Pathipati joined the Neurolens Board of Directors as a part of the financing.
The company also stated:
“The investment follows two recent announcements signaling the unprecedented acceleration of Neurolens within the vision industry. In late August, Inc. revealed that Neurolens had been recognized as the 28th fastest growing healthcare company on its annual Inc. 5000 list, a prestigious ranking of the fastest-growing private companies in America. Earlier in August, Neurolens released the results of a parallel arm study evaluating reading speed at baseline. The study revealed that after seven days of lens wear, the average improvement in reading speed with Neurolenses was almost 70% higher than the improvement seen with other premium lens designs.”